Compound 011
Alternative Names: Compound-011Latest Information Update: 11 Oct 2021
At a glance
- Originator Protheragen
- Class Antithrombotics; Small molecules
- Mechanism of Action MYH9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Thrombosis
Highest Development Phases
- Preclinical Thrombosis
Most Recent Events
- 11 Oct 2021 Compound 011 is available for licensing as of 11 Oct 2021. https://www.protheragen.com/available-projects/small-molecule-nmmhc-iia-inhibitors/
- 11 Oct 2021 Protheragen has patent protection for Compound 011 before October 2021 (Protheragen's pipeline, October 2021)
- 07 Oct 2021 Preclinical trials in Thrombosis in USA (unspecified route) before October 2021 (Protheragen's pipeline, October 2021)